ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership Operational Leadership Team Executes on Production and Commercialization of the Company's Immune Globulin Pro

ADMA Biologics Announces the Release

of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership

Operational Leadership Team Executes

on Production and Commercialization of the Company's Immune Globulin Product for the Treatment of Hepatitis B Infection

RAMSEY, N.J. and BOCA RATON, FL.,- April 24, 2018 -

ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), today announced that it has successfully

completed the manufacturing, release and has made commercial sales of its first batch of Nabi-HB ("Hepatitis B Immune

Globulin, Human"), produced under its leadership. ADMA Biologics is a vertically integrated commercial biopharmaceutical

company that manufactures, markets and develops specialty plasma-based biologics for the treatment of Primary Immune Deficiency

Disease ("PIDD") and the prevention and treatment of certain infectious diseases.

"We are pleased to announce that our team has successfully

manufactured, released and generated sales of our first production lot of Nabi-HB produced under ADMA's leadership since

the BTBU acquisition. We are continuing to make progress with our Compliance Enhancement Program to appropriately address the outstanding

compliance issues that we inherited from Biotest Pharmaceuticals when we purchased the Boca facility, and we continue to generate

revenues from the sale of commercial product and from our contract manufacturing services," said Adam Grossman, ADMA's

President and Chief Executive Officer. "We plan to provide updates on our manufacturing progress at the appropriate time."

As part of the Company's acquisition of the Biotest Therapy

Business Unit ("BTBU"), ADMA acquired the worldwide rights to Nabi-HB , along with raw materials and finished commercial

inventory, from which ADMA has generated accretive sales since closing the acquisition in June 2017. The commercially-released

batch of Nabi-HB enables the Company to fulfill ongoing demand for this specialty product.

ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a vertically integrated commercial biopharmaceutical

and specialty immunoglobulin manufacturing company that currently manufactures, markets and develops specialty plasma-based biologics

for the treatment of immune deficiencies and prevention of certain infectious diseases. ADMA's mission is to develop and

commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of

certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying

immune deficiency disease, or who may be immune-compromised for other medical reasons. ADMA has received U.S. Patents 9,107,906,

9,714,283 and 9,815,886 related to certain aspects of its lead product candidate, RI-002. For more information, please visit www.admabiologics.com.

Nabi-HB is a hyperimmune globulin that is rich in

antibodies to the Hepatitis B virus. Nabi-HB is a purified human polyclonal antibody product collected from plasma donors

who have been previously vaccinated with a Hepatitis B vaccine. Nabi-HB is indicated for the treatment of acute exposure to

blood containing Hepatitis B surface antigen ("HBsAg"), prenatal exposure to infants born to HBsAg-positive mothers,

sexual exposure to HBsAg-positive persons and household exposure to persons with acute Hepatitis B virus infection. Hepatitis B

is a potentially life-threatening liver infection caused by the Hepatitis B virus. It is a major global health problem and can

cause chronic infection and put people at high risk of death from cirrhosis and liver cancer. Nabi-HB has a well-documented

record of long-term safety and effectiveness since its initial market introduction. FDA approval for Nabi-HB was received

on March 24, 1999. Biotest acquired Nabi-HB from Nabi Biopharmaceuticals in 2007. ADMA resumed production of Nabi-HB

in the third quarter of 2017, as substantially all of the Nabi-HB inventory received as part of the Biotest Transaction has

been sold in the normal course of business.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements"

pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. ("we",

"our" or the "Company"). Forward-looking statements include, without limitation, any statement that may

predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate,"

"project," "intend," "forecast," "target," "anticipate," "plan,"

"planning," "expect," "believe," "will," "is likely," "will likely,"

"should," "could," "would," "may," or, in each case, their negative, or words or expressions

of similar meaning. These forward-looking statements also include, but are not limited to, statements concerning our plans to develop,

manufacture, market, launch and expand our own commercial infrastructure and commercialize our current products and future products,

the safety, efficacy and expected timing of, and our ability to, obtain and maintain regulatory approvals of our current products

and product candidates, and the labeling or nature of any such approvals, the success of our work with our third party vendors

and the U.S. Food and Drug Administration (the "FDA") in furtherance of and progress towards an approval of our Biologics

License Application for specialty plasma-based biologics and the ability of such third parties to respond adequately or in a timely

manner to the issues raised by the FDA, our ability to successfully pursue commercialization and prelaunch activities, the timeframe

within which we may receive approval from the FDA for specialty plasma-based biologics, if at all, the potential of our specialty

plasma-based biologics to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease or

other indications, our ability to realize increased prices for plasma growth in the plasma collection industry and our expectations

for future capital requirements. Actual events or results may differ materially from those described in this document due to a

number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the

forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties

inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation

or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if

at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking

statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks,

uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from

any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties

described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q

and 8-K, and any amendments thereto.

Vice President and Chief Financial Officer |201-478-5552 | www.admabiologics.com

INVESTOR RELATIONS CONTACT:

Managing Director, LifeSci Advisors, LLC | 917-749-1494 |